Hormonal
Metformin administration is associated with a reduced incidence of multiple age-related diseases and all-cause mortality in both diabetic and non-diabetic populations.
If you are taking metformin for diabetes, you may already be benefiting from reduced risks of age-related conditions. For non-diabetics considering metformin for longevity, the evidence is promising but not yet definitive (TAME trial pending). Discuss with your doctor, especially regarding kidney function and potential side effects like GI distress, which can often be managed with dosing strategies.
Several epidemiological studies demonstrated that metformin reduced the incidence of multiple age-related diseases as well as all-cause mortality. this phenomenon was observed not only in diabetic patients but also in non-diabetic patients [17, 18].
Why this rating
Based on observational/epidemiological studies and preclinical models; lacks definitive large-scale randomized controlled trials for non-diabetic aging (TAME trial mentioned as initiated).
Source
Metformin in aging and aging-related diseases: clinical applications and relevant mechanisms
Sheng Chen et al. · Theranostics · 2022
DOI 10.7150/thno.71360
More from this paper
- Metformin treatment improves outcomes in osteoarthritis (OA) by reducing inflammation, protecting articular cartilage via the AMPK pathway, and reducing body weight.Moderate
- Metformin use is associated with a reduced risk of various cancers, including breast, colorectal, and pancreatic cancer, though effects on pancreatic cancer prognosis are mixed.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →